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Abstract
Purpose—NRG Oncology RTOG 1014 is a prospective phase II trial of 3D-CRT PBrI following 
repeat lumpectomy for in-breast recurrence following previous whole breast irradiation (WBI). 
The primary goal of the trial was to determine the associated toxicity, tolerance and safety of PBrI.
Materials and Methods—Eligibility criteria included in-breast recurrence occurring >1 year 
following WBI, <3cm, unifocal and resected with negative margins. PBrI was targeted to surgical 
cavity + 1.5 cm; prescription dose of 45 Gy in 1.5Gy BID for 30 treatments was used. The primary 
objective was to evaluate the rate of grade ≥3 treatment-related skin, fibrosis, and/or breast pain 
adverse events (AEs), occurring ≤1 year from re-treatment completion. A rate of ≥13% for these 
AEs in a cohort of 55 patients was determined to be unacceptable, 86% power, 1-sided α=0.07.
Results—Between 2010 and 2013, 65 patients were accrued and the first 55 eligible and with 1 
year follow-up were analyzed. Median age is 68 years. 22 patients had DCIS and 33 invasive 
disease; 19 ≤1cm, 13 >1 to ≤2cm and 1 >2cm. All patients were clinically node-negative. 
Systemic therapy was delivered in 51%. All treatment plans underwent quality review for 
contouring accuracy and dosimetric compliance. All treatment plans scored acceptable for tumor 
volume (TV) contouring and TV dose volume analysis (DVA). Only 4 (7%) scored unacceptable 
for organs at risk (OAR) contouring and OAR DVA. Treatment-related skin, fibrosis, and/or breast 
pain AEs were recorded as grade 1 in 64%, grade 2 in 7% with only 1 (<2%) grade ≥3 and 
identified as grade 3 fibrosis of deep connective tissue.
Conclusion—PBrI with 3D-CRT following second lumpectomy for patients experiencing in-
breast failures after WBI is safe and feasible with acceptable treatment quality achieved. Skin, 
fibrosis and breast pain toxicity was acceptable and grade 3 toxicity was rare.
Keywords
breast cancer; breast cancer trials; re-treatment; partial breast radiation therapy for breast cancer
Introduction
Breast conservation surgery (BCS) followed by whole breast irradiation (WBI) yields 
excellent in-breast control rates and is recognized as a standard of care option for local 
treatment of properly selected patients. Long term follow-up of patients treated with BCS 
and WBI finds that in-breast failure rates are approximately 10%.1 Mastectomy is the 
acknowledged treatment of choice when encountering an in-breast failure following WBI. 
This has become accepted for reasons including the perception that mastectomy is the only 
logical next step, concerns over cosmetic outcomes following additional surgery and 
complication rates following additional radiotherapy. Published outcomes suggest that a 
mastectomy may not be the definitive answer, as chest wall failure rates following a 
mastectomy for in-breast failure after WBI range from 3–32%.2–15 (Table 1) It is recognized 
that these are older series with variable follow up and that the stage at presentation, in-breast 
recurrence extent and surgical details are not available to allow modern perspective 
regarding anticipated chest wall recurrence rates. However, this suggests that exploration of 
alternative options is appropriate. Attempts at continued breast conservation are represented 
through the limited series of repeat BCS alone that have been reported with poor in-breast 
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control rates.9,11,12,15,16 (Table 2) The lack of reported surgical margin status and 
description of imaging use make it difficult to extrapolate these results into present-day 
practice. Nevertheless, the rate of second in-breast failure is significant and consistent with 
results following lumpectomy only for primary disease. Whole breast irradiation in this 
setting is discouraged given the potential for serious late toxicity related re-irradiation of 
sensitive normal tissue such as lung and heart. The acceptance of partial breast irradiation as 
an alternative to whole breast irradiation in the setting of de novo breast conservation makes 
it a logical solution to apply to repeat breast conserving surgery in an attempt to reduce the 
2nd in-breast recurrence rates to acceptable levels while avoiding excessive toxicity. Early 
and limited investigation of this approach has generated outcome data that suggests this may 
be an appropriate direction to pursue if continued breast conservation is preferred.17–23 
(Tables 1 and 2).
Therefore, it is proposed that in properly selected patients facing an in-breast failure after 
initial lumpectomy and WBI, repeat BCS followed by partial breast re-irradiation (PBrI) 
could yield acceptable results. This manuscript is the first report from the NRG Oncology 
RTOG 1014 prospective phase II trial of 3D-conformal external beam (3D-CRT) PBrI 
following repeat lumpectomy for in-breast recurrence following previous WBI. The primary 
endpoint is to evaluate skin, breast, and chest wall adverse events (AEs) occurring within 1 
year from the completion of re-irradiation and is the focus of this report. Additional 
endpoints of local recurrence, cosmesis, and circulating tumor cells require additional 
follow-up and will be reported in the future.
Materials and Methods
Eligibility Criteria
Protocol approval was received from the Institutional Review Board at each study site and 
informed consent was obtained from each patient prior to participation. Patient eligibility 
criteria were defined to select patients with low likelihood of extensive in-breast recurrence 
with the risk of microscopic disease confined to the immediate vicinity of the lumpectomy 
cavity. In-breast failures could represent either delayed failure of the original tumor or a new 
primary within the same breast. Eligibility criteria included unicentric breast lesions by MRI 
that were ≤ 3 cm and without evidence of skin involvement, which occurred one year or 
more following initial breast conserving therapy. Histologically, recurrent tumors were to be 
consistent with invasive ductal, medullary, tubular, mucinous, lobular or ductal carcinoma in 
situ. Documentation of a negative metastatic work-up was required for invasive recurrences 
by either whole body Positron Emission Tomography - Computed Tomography (PET/CT) or 
a combined CT of the chest, abdomen, pelvis and bone scan. Being ≥ 18 years old and 
having breast conserving surgery with anticipated acceptable cosmesis and obtaining 
negative histologic margins of resection, no tumor on ink (re-excision was permitted to 
achieve negative margins) were requisites. Based on a postoperative, pretreatment CT scan 
the target lumpectomy cavity needed to be clearly defined and the target lumpectomy cavity/
whole breast reference volume <30% for study entry.
Axillary management was dependent on the in-breast recurrence histology and previous 
axillary surgery. Patients with 0–3 positive axillary lymph nodes without extracapsular 
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extension were eligible for enrollment. Axillary evaluation beyond a node negative clinical 
exam consisted of ultrasound, sentinel node evaluation and/or axillary node dissection 
(ALND) depending on histology and previous axillary surgery. Any suspicious areas were to 
be biopsied and if positive, followed with an ALND. Any patients presenting with a positive 
axillary clinical exam were required to undergo biopsy and if positive, follow with an 
ALND.
Target definition and dose delivery
Supine or prone treatment positioning was allowed and a treatment planning CT scan with 
required target volumes and organs at risk outlined on all CT slices was required. This 
included the clinical target volume (CTV), planning target volume (PTV) and PTV for 
Evaluation (PTV_EVAL), skin, ipsilateral and contralateral whole breast reference volume, 
thyroid, ipsilateral and contralateral lung, and heart (see Supplemental Appendix). The 
excision cavity was outlined based either on clear visualization on CT or, if placed, with the 
help of surgical clips. The CTV was defined by uniformly expanding the excision cavity 
volume by 15 mm with limitation to 5 mm from the skin surface and the posterior breast 
tissue extent (chest wall structures and pectoralis muscles were not included). The PTV 
provided a margin around the CTV to compensate for the variability of treatment setup and 
motion of the breast with breathing. The PTV was defined as a minimum of 10 mm around 
the CTV. The PTV_EVAL was generated and used for dose volume histogram analysis 
(DVA) constraints. The PTV_EVAL was defined as the PTV bounded and limited to exclude 
the first 5 mm of tissue under the skin and excludes any the PTV expansion beyond the 
posterior extent of breast tissue.
Dose delivery specifications included the use of 3D-CRT PBrI to begin within 9 weeks after 
last breast surgery. A total of 45 Gy was delivered in two fractions per day, each of 1.5 Gy, 
separated by at least six hours and given in fifteen consecutive working days for a total of 30 
fractions and 45 Gy.
Field arrangements were at the discretion of the physician and determined through 3D-
treatment planning to produce the optimal conformal plan in accordance with volume 
definitions. The treatment plan used for each patient was based on analysis of the volumetric 
dose including DVA of the PTV_EVAL and critical normal tissues. Dose calculations with 
tissue inhomogeneity correction were used. Photon field combinations (with or without 
electrons), and field within a field treatment approaches were accepted.
Quality assurance and rapid review
All cases were electronically submitted to the Image-Guided Therapy Quality Assurance 
Center (ITC) for review with final evaluation by one of the radiation oncology protocol 
investigators and judged as 1-per protocol, 2-variation acceptable or 3-deviation 
unacceptable. Quality assurance (QA) rapid reviews were to be done on the first case from 
each site before the start of treatment, unless previously participating on RTOG partial breast 
irradiation (PBI) protocols. The subsequent cases submitted to ITC were reviewed in a 
timely fashion with feedback of protocol guideline compliance to the participating 
institution as needed. QA reviews for all cases were completed prior to this report.
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Toxicity Assessment
Treatment related toxicity is documented with use of the Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 of the National Cancer Institute. Protocol stipulates 
evaluation and recording of any AEs occurring during radiation therapy, at 6 weeks from the 
start of treatment and then at regular intervals to follow (every 3 months for 1 year, every 4 
months for 2 years, every 6 months for 2 years and then annually).
Statistics
The primary objective of this study was to evaluate the rate (p) of grade ≥ 3 treatment-
related skin, fibrosis, and breast pain AEs, as graded by CTCAE version 4.0, occurring 
within 1 year from the completion of re-irradiation. Based on a rate of 4% for these AEs 
from first line PBrI treatment in RTOG 0319, the investigators determined that a rate of 13% 
or more for these AEs with re-irradiation would be unacceptable (H0: p ≤ 13% vs H1: p 
>13%). A sample size of 55 evaluable patients (eligible and started protocol treatment) 
provided the following: 86% power to conclude that the treatment has an unacceptable rate 
of the specified AEs, if the true AE rate is at least 13%, and 93% probability to not conclude 
that the treatment has an unacceptable rate of the specified AEs, if the true AE rate is ≤ 4%. 
Adjusting this figure by 10% to allow for patients determined to be ineligible, that did not 
start protocol treatment, or lack data, a total sample size of 61 patients was required for this 
study.
If 5 or more, out of 55 evaluable patients, experience the treatment-related AEs specified 
above, then that rate would be considered unacceptable and the treatment not be considered 
further; otherwise the treatment-related AE rate would be acceptable and the treatment 
considered for further study.
Results
This NRG Oncology RTOG 1014 was opened in June 2010 and completed accrual in June 
2013. In this 3 year time period, 34 RTOG members and affiliates/satellites participated, 
enrolling a total of 65 patients. Of those enrolled patients, 58 were determined to be 
ultimately eligible and received protocol treatment. As per protocol, this analysis is confined 
to the first 55 eligible patients who completed treatment and achieved 1 year of follow-up.
The overall compilation of pre-treatment patient and tumor characteristics are represented in 
Table 3. The median age is 68 years old (min-max: 44–86). The majority of cases consisted 
of invasive histology, 60% (n=33), with 40% (n=22) represented by ductal carcinoma in situ 
(DCIS). The invasive tumors were small (n=19 ≤1cm, n=13 >1 to ≤2cm, and n=1 >2cm) and 
the majority low to intermediate grade (69%) with only 31% high grade lesions. All tumors 
were tested for estrogen and progesterone receptors and 76.4% were estrogen positive and 
56% progesterone positive. Her2 testing was not available for 11 patients, but in those tested 
8 (18%) were positive with 36 (82%) negative. All patients were clinically node negative 
with 25% pathologically confirmed node negative. See Table 4 for axillary assessment 
details. The mean time between treatment for the initial breast disease and the in-breast 
failure was 14.9 years (median=14.0 years, min-max: 1.6–27.7). Systemic therapy was 
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delivered in 51% of patients, with systemic chemotherapy alone in 6 (10.9%) patients, 
hormone therapy alone in 21 (38.2%) patients, and both systemic chemotherapy and 
hormonal therapy in 1 (1.8%) patient.
Summary dose information is shown in Supplemental Table 1. Median PTV_EVAL volume 
is 242cc (min-max: 33.8–951.2cc), median ipsilateral breast volume is 1064cc (min-max: 
102.5–3103.4cc), and the median PTV_Eval volume/ipsilateral breast volume is 22% (min-
max: 7.7–49.3%). Overall contouring and dosimetric compliance was judged as 
exceptionally good with rare unacceptable variations. Details of dose constraint criteria and 
the ability to meet these constraints are shown in Table 5. Tumor volume contours were 
scored as per protocol in 52 (94.5%) cases, 3 (5.5%) cases were scored as acceptable 
variations and there were no unacceptable scores. Organs at risk (OAR) contours were 
scored as per protocol in 38 (69.1%) cases, 13 (23.6%) as acceptable variations, and only 4 
(7.3%) cases scored as unacceptable variations. High quality of treatment planning was 
confirmed through the dose volume analysis (DVA) score of tumor volume analysis and 
OAR. Tumor volume DVA were scored as per protocol in 54 (98.2%) cases, 1 (1.8%) as 
acceptable variation, and there were no unacceptable scores. OAR DVA were scored as per 
protocol in 45 (81.8%) cases, 5 (9.1%) as acceptable variations, and 5 (9.1%) cases as 
unacceptable variations. In review of the cases with unacceptable variation scores, 5 cases 
total were identified, 4 scoring unacceptable variation on both OAR contouring and OAR 
DVA and 1 scoring acceptable variation on OAR contouring and unacceptable variation on 
OAR DVA.
Treatment-related skin, fibrosis, and/or breast pain AEs are the primary endpoint for this 
phase II protocol. In the first 55 patients evaluable, these specific AEs were recorded as 
grade 1 in 64%, grade 2 in 7% with only 1 (<2%) grade 3. There were no grade 4 or 5 AEs 
reported. The skin and subcutaneous tissues disorders represented the majority of the 
reported grade 1 and grade 2 events. The documented grade 3 AE was represented by 
fibrosis of deep connective tissue (Table 6). Since there were fewer than 5 grade ≥ 3 
treatment-related skin, fibrosis, and breast pain AEs, the treatment-related AE rate is 
considered to be acceptable.
Discussion
This trial demonstrates acceptable toxicity and safety of a second breast conservation using 
lumpectomy and partial breast re-irradiation for management of in-breast recurrence 
following initial breast conservation where whole breast irradiation was delivered. Several 
publications have previously reported small experiences that describe early outcome results 
following repeat breast conservation and partial breast re-irradiation.18–23 Each experience 
has contributed to the overall understanding of this approach and helped to support the 
initiation of NRG Oncology RTOG 1014. One of the first experiences reported is from 
France where investigators offered repeat breast conservation treatment only to women that 
either refused mastectomy or when mastectomy was contraindicated.21 Treatment of the in-
breast failure consisted of re-resection followed by partial breast brachytherapy using 30Gy 
total dose delivered with low dose rate multicatheter brachytherapy (MCB). The study 
included 15 patients with a mean tumor size of 2.4 cm. Following this focused treatment, a 
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second in-breast recurrence was encountered in 26% (n=4 patients) at a mean follow-up of 
48 months. Major sequelae were reported in 3 patients. Of these 3, one patient with skin 
necrosis was treated with local wound care and one patient had a mastectomy performed.
Resch, et al, followed years later in 2002 with an additional small study. In this experience, 
17 patients were treated after encountering an in-breast failure following breast conserving 
therapy that included WBI.22 Nine patients followed local resection with 40–50 Gy partial 
breast treatment delivered with multicatheter technique. The remaining eight patients 
received repeat WBI to 30Gy followed by 12.5Gy delivered to a partial breast target with 
MCB. There were four second recurrences reported with a mean follow up of 50 months. 
Interestingly, all were within the group treated with repeat WBI and MCB. Toxicity was 
acceptable with only grade 1–2 fibrosis encountered.
Deutsch, et al., from the University of Pittsburgh Medical Center, published a study of repeat 
irradiation for in-breast tumor recurrence after prior lumpectomy and whole breast 
irradiation using external beam radiotherapy after re-resection.23 Thirty-nine patients were 
treated in this study, 31 invasive and 8 non-invasive diseases. All patients underwent 
resection of the recurrence to achieve negative pathologic margins with 15% of cases 
reported to ultimately have resection margins that were positive. Following local resection, 
external beam re-irradiation to the operative bed with 50 Gy in 25 fractions was delivered. 
At a median follow-up of 52 months, a second local in-breast recurrence was encountered in 
20.5% of patients. Contralateral breast cancer occurrence in this cohort study was also 
20.5%. There were no reports of radiation-induced necrosis.
Chadha, et al, published an additional experience from Beth Israel Medical Center in New 
York City, NY.20 This phase I/II study evaluated the role of partial breast MCB following 
local resection of a local recurrence/new primary following standard WBI. Fifteen patients 
were treated post lumpectomy with low dose rate brachytherapy utilizing a total of 30Gy for 
the first six patients and 45Gy for the subsequent nine patients. Median follow-up was 36 
months. They reported only one re-recurrence, and therefore, an overall in-breast control rate 
of 89%. No grade 3 or 4 toxicities reported.
In an additional small study published by Trombetta, et al., balloon based brachytherapy was 
used to deliver PBrI after local resection for in-breast failure following BCS and WBI.19 
Eighteen patients were included in this study and reported with a mean follow up of 39.6 
months. Results were again encouraging with only 2 patients recorded as having an in-breast 
re-recurrence and 2 patients with infection of which one required a mastectomy.
The largest study that has been published on this subject is the multicenter GEC-ESTRO 
European trial (The Groupe Européen de Curiethérapie (GEC) and the European Society for 
Radiotherapy & Oncology (ESTRO).18 This experience of 217 patients was reported in 2013 
with a mean follow up of 3.9 years. All patients had previously been treated with BCS and 
WBI and documented to have an in-breast failure. Repeat treatment on this trial consisted of 
local resection of the recurrent disease and MCB. They reported a 5-year actuarial re-
recurrence rate of only 5.6% with limited grade 3–4 complications (11%).
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The published literature corroborates the hypothesis of this trial that local resection followed 
by partial breast re-irradiation could be an appropriate alternative treatment approach to 
mastectomy for the local management of an in-breast failure following BCS and WBI. The 
growing experience in the use of 3D-CRT PBI and that it is widely available, reproducible, 
and could reliably deliver a homogeneous dose to previously irradiated tissue confirmed that 
this method needed to be studied in this setting. Furthermore, the established treatment 
guidance with existing outcome data from the previously successful RTOG 0319 phase II 
protocol provided a platform from which to build.24,25 To further reduce the risk of grade 3 
tissue toxicity, a hyperfractionated dose regimen was decided upon. This provided the 
opportunity to use a dose fractionation scheme modeled after the head and neck re-treatment 
experience − 1.5 Gy bid X 30 treatments and a total of 45 Gy.26–28 The intent was to assure 
the highest level of disease control and low risk of toxicity with optimal cosmetic outcome. 
Therefore, dose homogeneity and the dose fractionation scheme were believed to be 
optimized.
Conclusion
Initial AE data from NRG Oncology RTOG 1014 investigating PBrI with 3D-CRT following 
second lumpectomy for patients experiencing in-breast failures after lumpectomy and WBI 
suggests promising outcome and supports continued investigation. Despite previous whole 
breast irradiation, PBrI delivered with 3D-CRT is well tolerated and at the 1-year follow-up 
interval is found to be safe and feasible with acceptable treatment quality achieved. In the 
RTOG 0319 phase II protocol, 3D-CRT was used in an accelerated fashion (3.85Gy bid X 10 
delivered in 5 days) for primary breast conserving therapy for early stage breast cancer and 
reported a grade 3 toxicity event rate of 4%. In this trial of PBrI in patients with in-breast 
failure after WBI, a protracted hyperfractionated course of treatment was utilized. The 
fractionation scheme applied in this protocol was based on previous re-treatment 
experiences, however, it is recognized that alternative fractionation schemes may be 
appropriate. Grade 1 skin, fibrosis and breast pain was documented in a large number of 
patients as expected, however, grade 2 toxicity was infrequent at 7% and grade 3 toxicity 
was rare at <2%. This initial report suggests that the primary hypothesis, local resection 
followed by PBrI for an in-breast failure following WBI is safe and feasible, is correct. 
Further follow up is necessary for confirmation of long-term safety and to address the ability 
to achieve in-breast disease control with an acceptable long term cosmetic outcome and the 
ability to avoid mastectomy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This project was supported by grants U10CA21661 (RTOG-Ops-Stat), U10CA37422 (CCOP), U10CA180868 
(NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC) from the National Cancer Institute (NCI).
We would like to thank all the patients and institutions that participated in this trial.
Arthur et al. Page 8
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. Halperin, Edward CLWB., Perez, Carlos A., Wazer, David E. Perez & Brady's Principles and 
Practice of Radiation Oncology. 6. Philadelphia: Wolters Kluwer Health/Lippincott Williams & 
Wilkins; 2013. 
2. Clarke DH, Le MG, Sarrazin D, et al. Analysis of local-regional relapses in patients with early 
breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J 
Radiat Oncol Biol Phys. Jan; 1985 11(1):137–145. [PubMed: 2981790] 
3. Recht A, Schnitt SJ, Connolly JL, et al. Prognosis following local or regional recurrence after 
conservative surgery and radiotherapy for early stage breast carcinoma. Int J Radiat Oncol Biol 
Phys. Jan; 1989 16(1):3–9. [PubMed: 2912955] 
4. Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast-conserving surgery and 
radiotherapy. Frequency, time course, and prognosis. Cancer. May 15; 1989 63(10):1912–1917. 
[PubMed: 2702564] 
5. Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative 
management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys. Oct; 1989 
17(4):719–725. [PubMed: 2777661] 
6. Fowble B, Solin LJ, Schultz DJ, Rubenstein J, Goodman RL. Breast recurrence following 
conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from 
mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. Oct; 1990 
19(4):833–842. [PubMed: 2170305] 
7. Osborne MP, Borgen PI, Wong GY, Rosen PP, McCormick B. Salvage mastectomy for local and 
regional recurrence after breast-conserving operation and radiation therapy. Surg Gynecol Obstet. 
Mar; 1992 174(3):189–194. [PubMed: 1542833] 
8. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the 
conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. Jul; 1991 21(2):293–298. 
[PubMed: 2061106] 
9. Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the 
breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 
Jan; 1993 11(1):44–48. [PubMed: 8418240] 
10. Cajucom CC, Tsangaris TN, Nemoto T, Driscoll D, Penetrante RB, Holyoke ED. Results of 
salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy. 
Cancer. Mar 1; 1993 71(5):1774–1779. [PubMed: 8448741] 
11. Dalberg K, Mattsson A, Sandelin K, Rutqvist LE. Outcome of treatment for ipsilateral breast tumor 
recurrence in early-stage breast cancer. Breast Cancer Res Treat. May; 1998 49(1):69–78. 
[PubMed: 9694613] 
12. Voogd AC, van Tienhoven G, Peterse HL, et al. Local recurrence after breast conservation therapy 
for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study 
Group on Local Recurrence after Breast Conservation (BORST). Cancer. Jan 15; 1999 85(2):437–
446. [PubMed: 10023713] 
13. Doyle T, Schultz DJ, Peters C, Harris E, Solin LJ. Long-term results of local recurrence after breast 
conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys. Sep 1; 2001 51(1):
74–80. [PubMed: 11516854] 
14. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast 
conservation therapy based on location and histology: new primary tumors have more favorable 
outcomes than true local disease recurrences. Cancer. Nov 15; 2002 95(10):2059–2067. [PubMed: 
12412158] 
15. Salvadori B, Marubini E, Miceli R, et al. Reoperation for locally recurrent breast cancer in patients 
previously treated with conservative surgery. Br J Surg. Jan; 1999 86(1):84–87. [PubMed: 
10027366] 
16. Kurtz JM, Jacquemier J, Amalric R, et al. Is breast conservation after local recurrence feasible? Eur 
J Cancer. 1991; 27(3):240–244. [PubMed: 1827303] 
Arthur et al. Page 9
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
17. Kuerer HM, Arthur DW, Haffty BG. Repeat breast-conserving surgery for in-breast local breast 
carcinoma recurrence: the potential role of partial breast irradiation. Cancer. Jun 1; 2004 100(11):
2269–2280. [PubMed: 15160329] 
18. Hannoun-Levi JM, Resch A, Gal J, et al. Accelerated partial breast irradiation with interstitial 
brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: 
multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol. Aug; 
2013 108(2):226–231. [PubMed: 23647758] 
19. Trombetta M, Hall M, Julian TB. Long-term followup of breast preservation by re-excision and 
balloon brachytherapy after ipsilateral breast tumor recurrence. Brachytherapy. Sep-Oct;2014 
13(5):488–492. [PubMed: 24950822] 
20. Chadha M, Trombetta M, Boolbol S, Osborne MP. Managing a small recurrence in the previously 
irradiated breast. Is there a second chance for breast conservation? Oncology (Williston Park). Oct; 
2009 23(11):933–940. [PubMed: 19947343] 
21. Maulard C, Housset M, Brunel P, Delanian S, Taurelle R, Baillet F. Use of perioperative or split-
course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences 
after conservative management of breast cancer. Am J Clin Oncol. Aug; 1995 18(4):348–352. 
[PubMed: 7625378] 
22. Resch A, Fellner C, Mock U, et al. Locally recurrent breast cancer: pulse dose rate brachytherapy 
for repeat irradiation following lumpectomy-- a second chance to preserve the breast. Radiology. 
Dec; 2002 225(3):713–718. [PubMed: 12461250] 
23. Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after 
previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys. Jul 1; 2002 
53(3):687–691. [PubMed: 12062613] 
24. Vicini F, Winter K, Wong J, et al. Initial efficacy results of RTOG 0319: three-dimensional 
conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/ 
II breast carcinoma. Int J Radiat Oncol Biol Phys. Jul 15; 2010 77(4):1120–1127. [PubMed: 
19910132] 
25. Chafe S, Moughan J, McCormick B, et al. Late toxicity and patient self-assessment of breast 
appearance/satisfaction on RTOG 0319: a phase 2 trial of 3-dimensional conformal radiation 
therapy-accelerated partial breast irradiation following lumpectomy for stages I and II breast 
cancer. Int J Radiat Oncol Biol Phys. Aug 1; 2013 86(5):854–859. [PubMed: 23726000] 
26. Tercilla OF, Schmidt-Ullrich R, Wazer DE. Reirradiation of head and neck neoplasms using twice-
a-day scheduling. Strahlenther Onkol. May; 1993 169(5):285–290. [PubMed: 7684870] 
27. Spencer S, Wheeler R, Peters G, et al. Phase 1 trial of combined chemotherapy and reirradiation 
for recurrent unresectable head and neck cancer. Head Neck. Feb; 2003 25(2):118–122. [PubMed: 
12509794] 
28. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of 
reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head 
and neck. Head Neck. Mar; 2008 30(3):281–288. [PubMed: 17764087] 
Arthur et al. Page 10
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Summary
NRG Oncology RTOG 1014 is a phase II trial investigating partial breast re-irradiation 
(PBrI) with 3D-CRT following second lumpectomy for patients experiencing in-breast 
failures after whole breast irradiation (WBI). At the 1 year follow up interval, PBrI 
delivered with 3D-CRT technique is found to be well tolerated, safe and feasible with 
acceptable treatment quality achieved.
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Table 1
Chest wall failure rates following mastectomy for in-breast failure following lumpectomy and WBI
No. of pts Med. F/U (mo’s) Chest wall re-recurrence rate (%) 5-yr OS rates (%)
Clarke, et al, 1985 12 26 27 -
Recht, et al, 1989 65 32 9 -
Kurtz, et al, 1989 43 53 12a 53
Forquet, et al, 1989 39 63 - 73
Fowble, et al, 1990 52 25 - 84
**** 41 60 - 59
Osborne, et al, 1992 46 28 31 76
Abner, et al, 1993 106 39 7 79
Cajucom, et al, 1993 25 52 32 65
Dalberg, et al, 1998 65 156 19 -
Salvadori, et al, 1999 134 73 4 70
Doyle, et al, 2001 112 44 3 83
Huang, et al, 2002 118 84 20 52b
Abbreviations: No., number; Med., median; F/U, follow-up; mo’s, months; yr, year; OS, overall survival
a
chest wall and regional failures
b
true recurrences
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Table 2
In-breast re-recurrence rates following repeat lumpectomy only for in-breast failure following lumpectomy 
and WBI
No. of pts Med. f/u (mo’s) In-breast re-recurrence rate (%) 5-yr OS (%)
Kurtz, et al, 1991 55 51 27 -
Abner, et al, 1993 16 39 31 81
Dalberg, et al, 1998 14 156 50 -
Voogd, et al, 1999 16 52 38 -
Salvador, et al, 1999 57 73 19 85
Abbreviations: No., number; Med., median; F/U, follow-up; mo’s, months; yr, year; OS, overall survival
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Table 3
First 55 Evaluable Patients: Patient and Tumor Characteristics
Patient or Tumor Characteristic n %
Age (years)
 Median 68
 Min - Max 44 – 86
 Q1 – Q3 59 – 73
Race
 Asian 1 1.8
 Black or African American 8 14.5
 White 45 81.8
 Unknown 1 1.8
Zubrod Performance Status
 0 52 94.5
 1 3 5.5
Histology
 DCIS 22 40.0
 Invasive Histologies 33 60.0
  Size - largest dimension
  ≤ 0.5 cm 6 18.2
  >0.5 to ≤ 1.0 cm 13 39.4
  >1.0 to ≤ 2.0 cm 13 39.4
  >2.0 cm 1 3.0
Histology Grade
 Low grade 8 14.5
 Intermediate grade 30 54.5
 High grade 17 30.9
Stage (AJCC 7th Edition)
 Stage 0 21 38.2
 Stage I 33 60.0
 Stage IIA 1 1.8
Estrogen Receptor Status
 Positive 42 76.4
 Negative 13 23.6
Progesterone Receptor Status
 Positive 31 56.4
 Negative 24 43.6
Her2 Status
 Not applicable/Not done 11 20.0
 Positive 8 14.5
 Negative 36 65.5
Q1 = first quartile; Q3 = third quartile
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Table 4
First 55 Evaluable Patients: Information on Sentinel Lymph Nodes and Axillary Nodes (n=55)
Node Information n %
Invasive Lesions (n=33)
 No SLNB/No ALND 13 39.4
 SLN not identified/No ALND 8 24.2
 Yes SLNB/No ALND 9* 27.3
 Yes SLNB/Yes ALND 3* 9.1
DCIS (n=22)
 No SLNB/No ALND 18 81.8
 No SLNB/Yes ALND 1* 4.6
 SLN not identified/No ALND 2 9.1
 Yes SLNB/Yes ALND 1* 4.6
Abbreviations: SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection
*All node negative
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